Core Insights - Traditional treatments for Parkinson's disease only address symptoms and do not slow disease progression, prompting global research into the disease's mechanisms and targeted therapies [1][3] Group 1: Research and Development - The research team led by Professor Yu Jintai from Fudan University has identified a new therapeutic target, FAM171A2, and a candidate drug, bemcentinib, for Parkinson's disease, which has been recognized in the 2025 China Top Ten Scientific Advances [1][3] - The team utilized artificial intelligence for protein structure prediction and virtual screening, successfully identifying bemcentinib from over 7,000 compounds, which effectively inhibits the interaction between FAM171A2 protein and pathological alpha-synuclein [3] Group 2: Disease Prevalence and Economic Impact - In China, there are over 5 million Parkinson's disease patients, accounting for about half of the global total, with a projected doubling of patient numbers over the next 20 years due to aging [3] - The economic burden of Parkinson's disease in China is nearly 100 billion yuan annually, expected to rise to approximately 120 billion yuan by 2030 and further to 360 billion yuan by 2050 [4]
20年内患者数量将翻番，现每年经济负担近千亿元！帕金森病目前仍无特效药
Di Yi Cai Jing·2026-01-26 10:23